Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Account Payables (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Change in Account Payables for 7 consecutive years, with -$3000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 99.68% to -$3000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.5 million, a 483.75% decrease, with the full-year FY2025 number at -$5.5 million, down 483.75% from a year prior.
  • Change in Account Payables was -$3000.0 for Q4 2025 at Pliant Therapeutics, up from -$897000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q3 2024 to a low of -$4.2 million in Q2 2025.
  • A 5-year average of -$77150.0 and a median of $24500.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: crashed 2163.16% in 2022, then skyrocketed 1936.54% in 2023.
  • Pliant Therapeutics' Change in Account Payables stood at $490000.0 in 2021, then plummeted by 427.55% to -$1.6 million in 2022, then skyrocketed by 173.02% to $1.2 million in 2023, then plummeted by 179.35% to -$930000.0 in 2024, then soared by 99.68% to -$3000.0 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Change in Account Payables are -$3000.0 (Q4 2025), -$897000.0 (Q3 2025), and -$4.2 million (Q2 2025).